Get the Stockscreener App
2.84
20.34%
0.48
Kodiak Sciences Inc stock is traded at $2.84, with a volume of 705.75K.
It is up +20.34% in the last 24 hours and down -17.68% over the past month.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
See More
Previous Close:
$2.36
Open:
$2.36
24h Volume:
705.75K
Relative Volume:
1.94
Market Cap:
$114.99M
Revenue:
-
Net Income/Loss:
$-197.68M
P/E Ratio:
-0.7553
EPS:
-3.76
Net Cash Flow:
$-158.88M
1W Performance:
+35.56%
1M Performance:
-17.68%
6M Performance:
-13.94%
1Y Performance:
-21.11%
1-Day Range:
$2.34
$2.87
1-Week Range:
$2.02
$2.87
52-Week Range:
$1.92
$11.60
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1200 PAGE MILL RD, PALO ALTO, CA
Compare KOD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
2.84 | 114.99M | 0 | -197.68M | -158.88M | -3.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
April 2025's Promising Penny Stocks - Yahoo Finance
Age Related Vision Dysfunction Market to Reach New Heights - openPR.com
Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail
Wet Age-Related Macular Degeneration Therapeutics Market Size - openPR.com
Kodiak Sciences stock hits 52-week low at $2.15 - Investing.com India
HC Wainwright Comments on Kodiak Sciences Q2 Earnings - Defense World
HC Wainwright Forecasts Kodiak Sciences Q1 Earnings - Defense World
Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD) - Yahoo Finance
H.C. Wainwright holds Kodiak Sciences stock at Neutral, $3 target By Investing.com - Investing.com South Africa
H.C. Wainwright holds Kodiak Sciences stock at Neutral, $3 target - Investing.com
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Charles Schwab Investment Management Inc. Sells 6,758 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences Advances Retinal Therapies with Promising Pipeline - TipRanks
Kodiak Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
KODIAK SCIENCES Earnings Results: $KOD Reports Quarterly Earnings - Nasdaq
Kodiak Sciences Cuts Losses by 26%, Advances Two Phase 3 Trials with $168M War Chest - Stock Titan
Is Kodiak Sciences Inc. (KOD) The Hot Biotech Stock Under $5? - Insider Monkey
Bank of New York Mellon Corp Purchases 4,927 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Diabetic Macular Edema Pipeline 2025: Therapies Under - openPR
Kodiak Sciences Inc expected to post a loss of 88 cents a shareEarnings Preview - TradingView
Critical Contrast: Metagenomi (NASDAQ:MGX) & Kodiak Sciences (NASDAQ:KOD) - Defense World
10 Hot Biotech Stocks Under $5 - Insider Monkey
Retinal Vein Occlusion Clinical and Non-Clinical Studies, Key - openPR
KOD Completes Enrollment in Phase III Study for Eye Disease Candidate - MSN
Diabetic Retinopathy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Why Palantir (PLTR) Stock Is Up Today - The Globe and Mail
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy - Marketscreener.com
Kodiak Sciences completes enrollment in GLOW2 Phase 3 trial - TipRanks
KODKodiak Sciences Inc. Latest Stock News & Market Updates - StockTitan
CDC To Study Vaccines and Autism, Despite Much Research Showing No Link - 69News WFMZ-TV
Clinical Trial Success: Kodiak Enrolls 250+ Patients for Novel Diabetic Eye Drug - Stock Titan
Diabetic Retinopathy Pipeline 2025: Mechanism of Action, Route - openPR
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate - Yahoo Finance
Kodiak Sciences’ Anti-VEGF Could Win Nicely On Retinal Disorders (NASDAQ:KOD) - Seeking Alpha
Kodiak Sciences Inc. (NASDAQ:KOD) Sees Large Increase in Short Interest - MarketBeat
Elisa Oyj (OTCMKTS:ELMUF) Short Interest Update - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Sees Significant Growth in Short Interest - Defense World
166,843 Shares in Kodiak Sciences Inc. (NASDAQ:KOD) Bought by Peapod Lane Capital LLC - MarketBeat
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
SG Americas Securities LLC Has $209,000 Stock Holdings in Levi Strauss & Co. (NYSE:LEVI) - American Banking and Market News
SG Americas Securities LLC Has $206,000 Stake in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Diabetic Retinopathy Market on Track for Major Expansion by 2034, According to DelveInsight | Novartis, Kodiak Sciences Inc., Regenxbio, Perfuse Therapeutics, Hoffmann-La Roche, Boehringer Ingelheim - Barchart
Diabetic Retinopathy Market on Track for Major Expansion - openPR
Quarterly Dosing Breakthrough: Kodiak's New Glaucoma Treatment Targets Root Causes - StockTitan
Kodiak Sciences Inc.'s (NASDAQ:KOD) institutional investors lost 23% over the past week but have profited from longer-term gains - Simply Wall St
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kodiak Sciences Inc Stock (KOD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BORGESON JOHN A. | See Remarks |
Jun 12 '24 |
Sale |
2.92 |
1,558 |
4,549 |
179,544 |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):